SMART TECHNOLOGY PLATFORM
COMPOUNDS IN PIPELINE
Status in the preclinical stage
Dr. Yelena Wainman manages the CytoSwitch project. She completed her PhD in medicinal chemistry at the University of Cambridge followed by a post-doc at Harvard Medical School working on photoswitchable epigenetic inhibitors. She was active in the biotech/start-up scene in both Cambridge and Boston (Kaleidoscope, Palletech, Oxbridge Biotech Roundtable).
Dr. Doris Mangelberger carries out the in vivo validation for the new drug candidates at CytoSwitch. After a PhD in molecular biology at the Univ. of Salzburg, where she investigated signaling mechanisms involved in cancer formation, she did a postdoc at the Univ. of Michigan Cancer Center. There she developed skin cancer models for basic research and performed preclinical drug testing in vivo.
Tilmann Petersen manages the business related side of CytoSwitch. He has 10 years of experience as co-founder and manager in various Biotech and High-Tech Startups. He worked as Head of Finance in the VivoCell Biosolutions AG group, as CFO for Pioneers.io and as CEO of Nu Emotions.
Dr. Elena Longhi leads the synthetic efforts for the development of new compounds at CytoSwitch. She received her Ph.D. in industrial chemistry with a focus on organic chemistry from the Univ. of Milan. She then worked as a postdoc at Münster and Strasbourg universities, developing immunoassays for diagnostics, followed by a postdoc at Georgia Tech in organic electronics.
Franziska Ermer is working as a PhD Student on preclinical studies for our anticancer compounds in vitro and in vivo models. She became a board certified Veterinarian in April 2018 after studying at the Ludwig-Maximilians-Universität Munich (LMU). She carried out clinical veterinary internships in Germany and Australia focused on veterinary oncology.
Dr. Oliver Thorn-Seshold is the chemist behind the compound pipeline design for CytoSwitch. He leads a junior research group at the LMU Munich, developing small molecule inhibitors as reagents and cancer therapeutics. After a PhD in fluorescent probes at the University of Lyon, he began research into turning known cancer drugs into light-sensitive analogues.
CYTOSWITCH IN THE MEDIA